Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.

Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY.

Clin Vaccine Immunol. 2010 Apr;17(4):572-81. doi: 10.1128/CVI.00467-09. Epub 2010 Feb 24.


A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Holman DH, Penn-Nicholson A, Wang D, Woraratanadharm J, Harr MK, Luo M, Maher EM, Holbrook MR, Dong JY.

Clin Vaccine Immunol. 2009 Nov;16(11):1624-32. doi: 10.1128/CVI.00182-09. Epub 2009 Sep 23.


A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.

Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K.

J Virol. 2008 Jul;82(14):6927-34. doi: 10.1128/JVI.02724-07. Epub 2008 May 14.


Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.

Holman DH, Wang D, Raja NU, Luo M, Moore KM, Woraratanadharm J, Mytle N, Dong JY.

Vaccine. 2008 May 19;26(21):2627-39. doi: 10.1016/j.vaccine.2008.02.053. Epub 2008 Mar 14.


Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.

Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD.

Clin Vaccine Immunol. 2008 Mar;15(3):460-7. doi: 10.1128/CVI.00431-07. Epub 2008 Jan 23.


Acid ceramidase inhibition: a novel target for cancer therapy.

Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, Bielawski J, Dong JY, El-Zawahry AM, Guo GW, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Keane TE, Tavassoli M, Norris JS.

Front Biosci. 2008 Jan 1;13:2293-8. Review.


Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.

Schepp-Berglind J, Luo M, Wang D, Wicker JA, Raja NU, Hoel BD, Holman DH, Barrett AD, Dong JY.

Clin Vaccine Immunol. 2007 Sep;14(9):1117-26. Epub 2007 Jul 18.


Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells.

Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, Szulc ZM, Norris K, Zeidan YH, Hannun YA, Bielawska A, Norris JS.

Cancer Chemother Pharmacol. 2008 Feb;61(2):231-42. Epub 2007 Apr 12.


Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy.

Elojeimy S, Liu X, McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, Meacham WD, Mahdy AE, Saad AF, Turner LS, Cheng J, A Day T, Dong JY, Bielawska A, Hannun YA, Norris JS.

Mol Ther. 2007 Jul;15(7):1259-63. Epub 2007 Apr 10.


Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.

Raja NU, Holman DH, Wang D, Raviprakash K, Juompan LY, Deitz SB, Luo M, Zhang J, Porter KR, Dong JY.

Am J Trop Med Hyg. 2007 Apr;76(4):743-51.


Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.

Holman DH, Wang D, Raviprakash K, Raja NU, Luo M, Zhang J, Porter KR, Dong JY.

Clin Vaccine Immunol. 2007 Feb;14(2):182-9. Epub 2006 Dec 27.


Involvement of sphingolipids in apoptin-induced cell killing.

Liu X, Zeidan YH, Elojeimy S, Holman DH, El-Zawahry AM, Guo GW, Bielawska A, Bielawski J, Szulc Z, Rubinchik S, Dong JY, Keane TE, Tavassoli M, Hannun YA, Norris JS.

Mol Ther. 2006 Nov;14(5):627-36. Epub 2006 Aug 22.


New insights on the use of desipramine as an inhibitor for acid ceramidase.

Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, Mahdy A, Zeidan Y, Bielwaska A, Hannun YA, Norris JS.

FEBS Lett. 2006 Aug 21;580(19):4751-6. Epub 2006 Aug 4.


Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer.

Liu X, Elojeimy S, El-Zawahry AM, Holman DH, Bielawska A, Bielawski J, Rubinchik S, Guo GW, Dong JY, Keane T, Hannun YA, Tavassoli M, Norris JS.

Mol Ther. 2006 Nov;14(5):637-46. Epub 2006 Aug 1.


The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck.

Norris JS, Norris KL, Holman DH, El-Zawahry A, Keane TE, Dong JY, Tavassoli M.

Future Oncol. 2005 Feb;1(1):115-23. Review.


FasL gene therapy: a new therapeutic modality for head and neck cancer.

ElOjeimy S, McKillop JC, El-Zawahry AM, Holman DH, Liu X, Schwartz DA, Day TA, Dong JY, Norris JS.

Cancer Gene Ther. 2006 Aug;13(8):739-45. Epub 2006 Mar 17.


De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses.

Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY.

Vaccine. 2006 Apr 5;24(15):2975-86. Epub 2005 Dec 9.


In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.

Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS.

Cancer Gene Ther. 2005 Jan;12(1):12-8.


Supplemental Content

Loading ...
Support Center